XTL Biopharmaceuticals Ltd (XTLB) Cotización

XTLB.....................https://stockcharts.com/h-sc/ui?s=XTLB&p=W&b=5&g=0&id=p86431144783

XTLB under $3

XTLB......................................https://stockcharts.com/h-sc/ui?s=XTLB&p=W&b=5&g=0&id=p86431144783

XTLB under $3

XTLB new 52 hi

Schwabb won't let me short companies likes this.

Nice little pump and dump today.

Another scam Israeli company.

XTLB new 52 hi

$XTLB Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z

XTLB new 52 week hi

XTL To Aquire The Social Proxy

27k vol unusual vol 2 days before run looks like some insiders knew the news was coming …

running !

Halted shorts about to get ripped apart

News Watch Latest Pr Co Seeking Partnership/Merger

The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.

volume

$3.62 Macd crossover #bullish -> https://stockcharts.com/h-sc/ui?s=Xtlb

XTLb is continually looking for late stage products to in-license or acquire. In addition, we are pursuing partnerships for the development and marketing of our products internationally. If your company has interest in discussing a potential business collaboration with XTL, please contact our business development department at: bd@xtlbio.com or call us at +972 9 955 7080.

Company is seeking merger / partnership The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.

* * $XTLB Video Chart 03-05-2021 * *

Link to Video - click here to watch the technical chart video

Thanks for the link. Other boards seem to be clueless as to why the sharp increase in price.$XTLB

$XTLB is screaming for the top after a recent report shows massive growth in the company's target market. This is a clear acquisition target! https://cnafinance.com/xtlb-stock-xtl-biopharmaceuticals-is-rocketing/

Good lord

$1.70 nice

http://barchart.com/quotes/stocks/XTLBY

* * $XTLB Video Chart 05-07-18 * *

Link to Video - click here to watch the technical chart video

Boom!!!

hmmm

55k

What was the volume AH yesterday?

There is some 3,50 Gifts

Woow afterhour

XTLB bullish 1.22

Whose driving this bus today, any catalyst here? GLTA!!!

Will def have this on my radar; ready to jump in with any momentum....

I must have missed the pump too

XTLB is a clear pump and dump based on charting. The company hasn't had any news in over a month. Claim your shares to short now.

Multi-day run?

http://finance.yahoo.com/news/xtl-biopharmaceuticals-further-strengthens-team-120000879.html

(XTLB) Very good time to short it.

Boom...another pick skyrocket from BackPackOfStock

No idea

What happen?.

Wowwowowowowowowoowow

Just picked a few shares....heard rumblings

8:02AM XTL Biopharma announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, (XTLB) 2.73 : Co announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus.

Two placebo controlled Phase I trials and a placebo controlled Phase II trial were conducted by Teva Pharmaceutical (TEVA) which had previously in-licensed hCDR1 from Yeda. The Phase I and Phase II studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed impressive results for this dose using the BILAG index. Such dose will be the focus of the clinical development plan moving forward.

The FDA has since directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the BILAG index or the SLE Responder Index. Given the FDA's recommendation and the positive findings from the PRELUDE trial, XTL intends to initiate a new Phase II clinical trial, which will include the 0.5 mg (and a 0.25 mg) weekly dose of hCDR1.

XTLBY changed to XTLB and uplisted to the Nasdaq NCM:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/12/2013&mkt_ctg=NON-OTCBB

XTLBY: 1-10 R/S concurrent with a ratio change. The ADR Ratio will change from [ one(1) ADS: two (2) Ordinary Share] to a new ratio of [ one (1) ADS: twenty (20) Ordinary Share]. Holders of XTL BioPharmaceuticals will be required on a mandatory basis to surrender their Old ADSs to BNY Mellon in exchange for the New ADSs. ONly whole DRs will be distributed.

http://www.otcbb.com/asp/dailylist_detail.asp?d=10/03/2012&mkt_ctg=NON-OTCBB

Hello,
Is there more information over XTLBY?